Project Grant R21AI187979
Award Date 8/18/25
Completion Date 7/31/27
Dollars Obligated $162K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,710,680 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to The Methodist Hospital Research Institute (HMRI) in Houston, Texas. The funding supports the development of new generation mRNA-based vaccines against tuberculosis (TB) that integrate protective antigenic epitopes from Mycobacterium tuberculosis and self-adjuvant peptides to boost immune responses. The...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $314,363 to Via Therapeutics, LLC, a for-profit limited liability company based in Austin, Texas, to develop a microneedle-based mRNA flu vaccine candidate for transcutaneous immunization. The goal is to create a stable, multivalent mRNA flu vaccine that can be administered intradermally using proprietary thin-film...
- This federal Project Grant award of $798,400.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on May 5, 2025. The grant is intended to fund research by the University of Texas Medical Branch at Galveston (UTMB) to develop a circular RNA vaccine construct against the Andes virus, a hantavirus that causes severe cardiopulmonary syndrome. The research aims to improve the durability of the...
- This cooperative agreement, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research grant program (CFDA 93.855), provides $1,673,641 in funding to Boston Children's Hospital to conduct a Phase 1 clinical study on a novel mRNA-based SARS-CoV-2 vaccine candidate. The vaccine utilizes two key innovations: 1) a multi-organ protection mRNA sequence that constrains expression to the injection site, and 2) an mRNA-encoded...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is supporting the development of a unique vaccine to prevent future pandemics caused by emerging coronaviruses. The $755,225 award to Loyola University of Chicago aims to create a T cell-inducing mucosal vaccine targeting conserved coronavirus antigens, which could provide cross-protection against sarbecoviruses and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $929,500 to the Icahn School of Medicine at Mount Sinai to investigate the mechanisms of action for mRNA-based and Newcastle Disease Virus (NDV)-based COVID-19 vaccine platforms in inducing mucosal immune responses. The researchers aim to understand how these vaccine platforms can elicit long-lasting protective systemic and mucosal immunity...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $114,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of Colorado, doing business as the University of Colorado-Denver. The grant, awarded on November 1, 2025, will fund research to investigate the role of type 1 interferon signaling on vaccine stability within lymphatic endothelial cells. Specifically, the project aims to: (1) Determine if type 1...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $122,597 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Texas Health Science Center at San Antonio. The grant, which runs from January 2025 to September 2027, will support research to analyze the function and antibody-mediated inhibition of the malaria vaccine candidate PF3D7_1136200. This highly conserved Plasmodium falciparum protein is a promising...
- This $676,666.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a self-amplifying mRNA (saRNA) influenza vaccine delivered via a microneedle array patch. The project aims to optimize the antigen expression, immunogenicity, and efficacy of the saRNA flu vaccine and evaluate the optimal timing and delivery method (intranasal or intradermal) of a proprietary adjuvant to...